Pura Vida Investments’s United Therapeutics UTHR Stock Holding History

Pura Vida Investments’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-36,333	Closed	-$10.1M	–	173
2022 Q4	$10.1M	Sell	36,333 -88,713	-71%	-$22.4M	0.52%	52
2022 Q3	$26.2M	Buy	125,046 +64,396	+106%	+$14.4M	1.51%	18
2022 Q2	$14.3M	Buy	60,650 +44,089	+266%	+$8.96M	0.83%	35
2022 Q1	$2.97M	Buy	16,561 +5,803	+54%	+$1.11M	0.1%	146
2021 Q4	$2.33M	Buy	10,758 +2,171	+25%	+$426K	0.08%	144
2021 Q3	$1.58M	Buy	+8,587	New	+$1.69M	0.05%	200
2019 Q4	–	Sell	-39,000	Closed	-$3.11M	–	122
2019 Q3	$3.11M	Hold	39,000	–	–	0.53%	52
2019 Q2	$3.04M	Buy	+39,000	New	+$3.65M	0.46%	67
2018 Q2	–	Sell	-20,000	Closed	-$2.25M	–	113
2018 Q1	$2.25M	Sell	20,000 -909	-4%	-$115K	1.33%	26
2017 Q4	$3.09M	Buy	+20,909	New	+$2.66M	1.29%	33

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Pura Vida Investments's UTHR Position: Q1 2023 in Review

Pura Vida Investments sold out of United Therapeutics (UTHR) in Q1 2023, closing a stake of 36,333 shares — an estimated $10.1M sold.

Pura Vida Investments first reported a position in UTHR in Q4 2017 and held it in 10 quarters. The position peaked at $26.2M in Q3 2022. 506 funds tracked by Wall St. Rank hold UTHR as of Q1 2023.

Pura Vida Investments reported no remaining United Therapeutics position as of Q1 2023 after selling out during the quarter.
Pura Vida Investments sold 36,333 United Therapeutics shares in Q1 2023, an estimated $10.1M.
Pura Vida Investments first reported a position in United Therapeutics in Q4 2017 and held it in 10 quarters.
Pura Vida Investments's United Therapeutics position peaked at $26.2M in Q3 2022.
506 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2023.

Based on Pura Vida Investments's 13F filing for Q1 2023, filed 15 May 2023.